At the present stage Worg is developing allergy immunotherapy (AIT) for patients with allergic rhinitis, allergic conjunctivitis and allergic asthma to improve their quality of life and to offer better solutions than the current symptomatic treatments.

Worg has recently acquired the world-wide rights of a comprehensive pipeline of PCFiT-based allergy vaccines for a number of inhalant allergens. The Company intends to expand this pipeline through collaborations and internal research with an emphasis of highly prevalent allergens in China and other regions.